{
  "ticker": "GMAB",
  "company_name": "Genmab A/S",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT06796998",
      "title": "Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)",
      "status": "RECRUITING",
      "phase": "PHASE2",
      "condition": "Marginal Zone Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Splenic Marginal Zone Lymphoma, Nodal Marginal Zone Lymphoma",
      "start_date": "2025-10-13",
      "completion_date": "2031-04-15",
      "enrollment": 0,
      "sponsor": "Izidore Lossos, MD"
    },
    {
      "nct_id": "NCT06458439",
      "title": "Epcoritamab-CAR T Cells for Large B-cell Lymphomas",
      "status": "RECRUITING",
      "phase": "PHASE2",
      "condition": "Lymphoma, Non-Hodgkin, Relapsed Diffuse Large B Cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma, Transformed Indolent Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma",
      "start_date": "2024-09-24",
      "completion_date": "2027-12",
      "enrollment": 0,
      "sponsor": "Abramson Cancer Center at Penn Medicine"
    },
    {
      "nct_id": "NCT06046274",
      "title": "GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer",
      "status": "WITHDRAWN",
      "phase": "PHASE2",
      "condition": "Advanced Endometrial Cancer",
      "start_date": "2023-10-01",
      "completion_date": "2028-06-01",
      "enrollment": 0,
      "sponsor": "Genmab"
    },
    {
      "nct_id": "NCT03625037",
      "title": "First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "DLBCL, High-grade B-cell Lymphoma (HGBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL), FL, MCL, Small Lymphocytic Lymphoma (SLL), Marginal Zone Lymphoma (MZL), Indolent B-cell Non-Hodgkin Lymphoma (iNHL), Aggressive B-cell Non-Hodgkin Lymphoma (aNHL)",
      "start_date": "2018-06-26",
      "completion_date": "2029-01",
      "enrollment": 0,
      "sponsor": "Genmab"
    },
    {
      "nct_id": "NCT05409066",
      "title": "Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "condition": "Follicular Lymphoma (FL)",
      "start_date": "2022-09-20",
      "completion_date": "2029-12",
      "enrollment": 0,
      "sponsor": "Genmab"
    },
    {
      "nct_id": "NCT06952660",
      "title": "Ocular Assessments in Patients Treated With Tivdak\u00ae in Recurrent or Metastatic Cervical Cancer",
      "status": "RECRUITING",
      "phase": "PHASE4",
      "condition": "Cervical Cancer",
      "start_date": "2025-05-07",
      "completion_date": "2028-12-13",
      "enrollment": 0,
      "sponsor": "Pfizer"
    },
    {
      "nct_id": "NCT05451810",
      "title": "A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "condition": "Diffuse Large B-Cell Lymphoma, Classic Follicular Lymphoma",
      "start_date": "2022-08-17",
      "completion_date": "2027-03",
      "enrollment": 0,
      "sponsor": "Genmab"
    },
    {
      "nct_id": "NCT03913741",
      "title": "A Trial of Tisotumab Vedotin in Japanese Subjects With Advanced Solid Malignancies",
      "status": "COMPLETED",
      "phase": "PHASE1, PHASE2",
      "condition": "Solid Tumor",
      "start_date": "2019-02-27",
      "completion_date": "2021-10-30",
      "enrollment": 0,
      "sponsor": "Genmab"
    },
    {
      "nct_id": "NCT06919939",
      "title": "Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma",
      "status": "RECRUITING",
      "phase": "PHASE2",
      "condition": "Large B-cell Lymphoma, Relapse",
      "start_date": "2026-02-01",
      "completion_date": "2031-02-01",
      "enrollment": 0,
      "sponsor": "University of Miami"
    },
    {
      "nct_id": "NCT04937153",
      "title": "GEN1046 Safety and PK in Subjects With Advanced Solid Malignancies",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Solid Tumor",
      "start_date": "2021-06-15",
      "completion_date": "2024-10-01",
      "enrollment": 0,
      "sponsor": "Genmab"
    }
  ],
  "summary": {
    "total_trials": 50,
    "by_phase": {
      "PHASE2": 16,
      "PHASE1, PHASE2": 18,
      "PHASE3": 5,
      "PHASE4": 1,
      "PHASE1": 6,
      "": 3,
      "PHASE2, PHASE3": 1
    },
    "by_status": {
      "RECRUITING": 16,
      "WITHDRAWN": 2,
      "ACTIVE_NOT_RECRUITING": 16,
      "COMPLETED": 6,
      "TERMINATED": 8,
      "NO_LONGER_AVAILABLE": 1,
      "APPROVED_FOR_MARKETING": 1
    },
    "active_trials": 32,
    "completed_trials": 6,
    "conditions": [
      "Advanced Endometrial Cancer",
      "Advanced Malignant Solid Tumor",
      "Advanced Malignant Solid Tumors, Metastatic Malignant Solid Tumors",
      "B-Cell Non-Hodgkin Lymphoma",
      "Breast Cancer, Breast Neoplasms, Endometrial Cancer, Endometrial Neoplasm, Ovarian Cancer, Ovarian Neoplasms, Squamous Non Small Cell Lung Cancer (NSCLC-SCC)",
      "Cervical Cancer",
      "Classical Hodgkin Lymphoma, Non-Hodgkin Lymphoma",
      "Colorectal Cancer",
      "Cutaneous T-Cell Lymphoma",
      "DLBCL, High-grade B-cell Lymphoma (HGBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL), FL, MCL, Small Lymphocytic Lymphoma (SLL), Marginal Zone Lymphoma (MZL), Indolent B-cell Non-Hodgkin Lymphoma (iNHL), Aggressive B-cell Non-Hodgkin Lymphoma (aNHL)",
      "Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Small Lymphocytic Lymphoma",
      "Diffuse Large B-Cell Lymphoma",
      "Diffuse Large B-Cell Lymphoma Post-Transplant Lymphoproliferative Disorder, EBV-Related Post-Transplant Lymphoproliferative Disorder, Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder, Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder, Refractory Monomorphic Post-Transplant Lymphoproliferative Disorder, Refractory Polymorphic Post-Transplant Lymphoproliferative Disorder",
      "Diffuse Large B-Cell Lymphoma, Classic Follicular Lymphoma",
      "Diffuse Large B-Cell Lymphoma, Follicular Lymphoma",
      "Diffuse Large B-cell Lymphoma",
      "Diffuse Large B-cell Lymphoma, Follicular Lymphoma",
      "Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, High-grade B-cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma",
      "Endometrial Cancer, Ovarian Cancer, Triple Negative Breast Cancer, GastroEsophageal Cancer, Non-small Cell Lung Cancer, Urothelial Carcinoma",
      "Follicular Lymphoma (FL)",
      "Follicular Lymphoma, Low Grade Non-Hodgkin's Lymphoma, Adult",
      "Head and Neck Cancer, Squamous Cell Cancer",
      "Head and Neck Cancer, Squamous Cell Carcinoma",
      "Head and Neck Neoplasms",
      "High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, Breast Adenocarcinoma, Triple Negative Breast Cancer, Hormone Receptor-positive/Her2 Negative Breast Cancer, Platinum-resistant Ovarian Cancer (PROC), Platinum Sensitive Ovarian Cancer (PSOC), Primary Refractory Ovarian Cancer, Uterine Cancer",
      "Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Primary Mediastinal Large B-cell Lymphoma (PMBCL), High Grade B-cell Lymphoma (HGBCL), Grade 3B Follicular Lymphoma",
      "Large B-cell Lymphoma, Relapse",
      "Large Cell Lymphoma, Diffuse, Relapsed Cancer, Refractory Cancer",
      "Locally Advanced or Metastatic Solid Tumor(s), Prostate Cancer, Esophageal Cancer, Triple Negative Breast Cancer (TNBC), Squamous Cell Carcinoma of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Bladder Cancer, Uterine Cancer",
      "Lymphoma",
      "Lymphoma, Non-Hodgkin, Relapsed Diffuse Large B Cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma, Transformed Indolent Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma",
      "Malignant Solid Tumor",
      "Marginal Zone Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Splenic Marginal Zone Lymphoma, Nodal Marginal Zone Lymphoma",
      "Metastatic Colorectal Cancer",
      "Non Small Cell Lung Cancer Metastatic",
      "Non-hodgkin Lymphoma",
      "Non-small Cell Lung Cancer",
      "Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer",
      "Ovarian Cancer, Platinum-sensitive Ovarian Cancer, PSOC",
      "PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC",
      "Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma",
      "Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome, Treatment-na\u00efve High Risk Chronic Lymphocytic Leukemia",
      "Rheumatoid Arthritis",
      "Solid Tumor",
      "Solid Tumors, Non-small Cell Lung Cancer, Urothelial Carcinoma, Endometrial Carcinoma, Triple Negative Breast Cancer, Squamous Cell Carcinoma of the Head and Neck, Cervical Cancer",
      "Waldenstrom Macroglobulinemia, B-Cell Lymphoproliferative Disorder"
    ],
    "lead_stage": "commercial"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:18:41.047972",
    "search_query": "Genmab A/S",
    "url": "https://clinicaltrials.gov/search?term=Genmab+A/S"
  }
}